TCBIR/CD320: a potential therapeutic target upregulated in endothelial cells and associated with immune cell infiltration in liver hepatocellular carcinoma.

MLA

Zhang, Shubin, et al. “TCBIR/CD320: A Potential Therapeutic Target Upregulated in Endothelial Cells and Associated with Immune Cell Infiltration in Liver Hepatocellular Carcinoma.” Discover Oncology, vol. 15, no. 1, July 2024, p. 255. EBSCOhost, https://doi.org/10.1007/s12672-024-01122-w.

APA

Zhang, S., Jiang, Z., Wang, P., Jiang, W., Ding, W., & Zhong, L. (2024). TCBIR/CD320: a potential therapeutic target upregulated in endothelial cells and associated with immune cell infiltration in liver hepatocellular carcinoma. Discover Oncology, 15(1), 255. https://doi.org/10.1007/s12672-024-01122-w

Chicago

Zhang, Shubin, Zhongyi Jiang, Pusen Wang, Weihao Jiang, Wei Ding, and Lin Zhong. 2024. “TCBIR/CD320: A Potential Therapeutic Target Upregulated in Endothelial Cells and Associated with Immune Cell Infiltration in Liver Hepatocellular Carcinoma.” Discover Oncology 15 (1): 255. doi:10.1007/s12672-024-01122-w.